Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations

PLoS Medicine

Volumn 5, Issue 7, 2008, Pages 1033-1036

  Hanekom, Willem A ^a   Dockrell, Hazel M ^b   Ottenhoff, Tom H M ^c   Doherty, T Mark ^d   Fletcher, Helen ^e   McShane, Helen ^e   Weichold, Frank F ^f   Hoft, Dan F ^g   Parida, Shreemanta K ^h   Fruth, Uli J ⁱ  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d STATENS SERUM INSTITUT   (Denmark)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f Aeras Global Tuberculosis Vaccine Foundation   (United Kingdom)

^g SAINT LOUIS UNIVERSITY   (United States)

^h MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

ⁱ WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

CELL ASSAY; CELL ISOLATION; CLINICAL TRIAL; CRYOPRESERVATION; HUMAN; IMMUNOGENICITY; IMMUNOLOGY; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRACTICE GUIDELINE; SHORT SURVEY; STANDARDIZATION; T LYMPHOCYTE; THAWING; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION; ARTICLE; CLINICAL TRIAL (TOPIC); HEALTH CARE PLANNING; METHODOLOGY; STANDARD; TREATMENT OUTCOME; TUBERCULOSIS;

CLINICAL TRIALS AS TOPIC; HEALTH PLANNING GUIDELINES; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS VACCINES; WORLD HEALTH ORGANIZATION;

EID: 48749119738     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050145     Document Type: Short Survey

References (11)

1. Flynn JL (2004) Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb) 84: 93-101.
2. Kaufmann SH, Baumann S, Nasser Eddine A (2006) Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis. Int J Tuberc Lung Dis 10: 1068-1079.
3. Martin C (2006) Tuberculosis vaccines: Past, present and future. Curr Opin Pulm Med 12: 186-191.
4. Skeiky YA, Sadoff JC (2006) Advances in tuberculosis vaccine strategies. Nat Rev Microbiol 4: 469-476.
5. Lauvau G, Pamer EG (2001) CD8 T cell detection of bacterial infection: Sniffing for formyl peptides derived from Mycobacterium tuberculosis. J Exp Med 193:F35-F39.
6. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, et al. (2002) HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 3: 1061-1068.
7. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712.
8. Disis ML, dela Rosa C, Goodell V, Kuan LY, Chang JC, et al. (2006) Maximizing the retention of antigen specific lymphocyte function after cryopreservation. J Immunol Methods 308: 13-18.
9. Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, et al. (2007) Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 323: 39-54.
10. Maecker HT, Moon J, Bhatia S, Ghanekar SA, Maino VC, et al. (2005) Impact of cryo preservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol 6: 17.
11. Mittrucker HW, Steinhoff U, Kohler A, Krause M, Lazar D, et al. (2007) Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis. Proc Natl Acad Sci U S A 104: 12434-12439.